Sponsored Breakfast Symposium: Recent advances in pharmacological strategies to prevent exacerbations of COPD
Sunday 25th March
Synopsis: COPD exacerbations have a negative impact on the quality of life of patients with COPD, accelerates disease progression and can result in hospital admissions and death. In Australia, COPD is the second leading cause of avoidable hospital admissions and remains the fifth leading cause of death.1 Identifying patients at risk of exacerbations and managing them appropriately to reduce this risk represents an important clinical challenge. COPD exacerbations are heterogeneous events and recent advances in understanding this heterogeneity have improved the development and implementation of therapies for COPD patients. The use of inhaled combination therapies in the treatment of COPD continues to evolve. The IMPACT (InforMing the Pathway of COPD Treatment) study will further advance understanding of the optimal use of inhaled combination therapies in the treatment of COPD. This symposium explores the current and new pharmacological strategies in the prevention of COPD exacerbations.
Sponsored Breakfast Symposium: Recent advances in pharmacologicalstrategies to
prevent exacerbations of COPD
|0700-0705||Opening remarks||Christine Jenkins, NSW|
|0705-0725||COPD pharmacotherapies: Old targets, new insights, new targets needed||Alastair Stewart, VIC|
|0725-0750||Preventing COPD exacerbations: Pharmacotherapeutic approaches in 2018||Philip Bardin, VIC|
|0750-0805||Exacerbation benefit and pneumonia risk: A composite outcome||Grant Waterer, WA|
|0805-0815||Q and A|
Sponsored Evening Symposium: Maximising Outcomes Across the Asthma Spectrum
Sunday 25 March
Synopsis: Asthma is a common, complex, and heterogeneous disease characterised by multiple clinical phenotypes and biologic endotypes. Patients present across a wide spectrum of disease severity with varying levels of control. This is further complicated by a plethora of co-existing morbidities in addition to various barriers to patient self-management related to psycho-social and socio-economic factors.
How do we optimise asthma management within this landscape?
How do we tailor treatment to the individual patient and improve self-management across the spectrum of disease?
When and in which patients should we consider a different approach or consider newer strategies including biologic agents?
This symposium will ask the audience to consider some of the challenges in the management of asthma including the questions above and propose potential solutions or strategies in pursuit of ‘Maximising Outcomes Across the Asthma Spectrum’.
Sponsored Evening Symposium: Maximising outcomes across the asthma spectrum
|1715-1730||Drinks and canapes|
|1730-1735||Welcome and introduction by chair|
|1735-1755||The asthma paradox: What is it and how do we deal with it?||Christine Jenkins, NSW|
|1755-1815||Redefining optimal care in moderate-severe asthma||John Upham, QLD|
|1815-1845||Managing severe asthma patients in the era of biologic agents||Tim Harrison, UK|
Sponsored Evening Symposium: Unravelling the complexities of Idiopathic Pulmonary Fibrosis (IPF) treatment in 2018
Monday 26 March
Synopsis: This symposium will focus on providing clarity on when to intervene, what to do if patients deteriorate including the challenges faced along the treatment journey and what choices the clinical team faces. A/Prof Daniel Chambers will chair the meeting with Prof Vincent Cottin unravelling evidence on the highly variable lung function decline and progression in IPF clinical studies, including what measurements to utilise and how to determine if a patient has progressed. A/Prof Glen Westal will address the important topic of lung transplantation, such as local criteria. Dr. Lauren Troy will conclude discussing survival and the evidence on predicting survival.
Sponsored Evening Symposium: Unravelling the complexities of Idiopathic
|1715-1745||Drinks and canapes|
Vincent Cottin, France
Glen Westall, VIC
Lauren Troy, NSW